S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:ADMAADMA Biologics Stock Price, Forecast & News

$2.87
-0.17 (-5.59 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.86
Now: $2.87
$3.04
50-Day Range
$2.76
MA: $3.02
$3.74
52-Week Range
$1.45
Now: $2.87
$5.48
Volume3.69 million shs
Average Volume3.16 million shs
Market Capitalization$247.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Read More
ADMA Biologics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.35 million
Book Value$0.44 per share

Profitability

Net Income$-48,280,000.00
Net Margins-164.90%

Miscellaneous

Employees314
Market Cap$247.81 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$2.87
-0.17 (-5.59 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

How has ADMA Biologics' stock been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADMA stock has increased by 24.2% and is now trading at $2.87.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ADMA Biologics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ADMA Biologics
.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ADMA Biologics
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07. ADMA Biologics had a negative return on equity of 104.32% and a negative net margin of 164.90%.
View ADMA Biologics' earnings history
.

What price target have analysts set for ADMA?

4 analysts have issued twelve-month price objectives for ADMA Biologics' stock. Their forecasts range from $4.00 to $12.00. On average, they expect ADMA Biologics' stock price to reach $7.00 in the next year. This suggests a possible upside of 143.9% from the stock's current price.
View analysts' price targets for ADMA Biologics
.

What are Wall Street analysts saying about ADMA Biologics stock?

Here are some recent quotes from research analysts about ADMA Biologics stock:
  • 1. According to Zacks Investment Research, "ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey. " (8/7/2020)
  • 2. Maxim Group analysts commented, "ADMA announced (8/22) that the relaunch of BIVIGAM has commenced. BIVIGAM is available through authorized distributor BioCareSD (Private). Launch for ASCENIV should follow in 2H19." (8/27/2019)

Has ADMA Biologics been receiving favorable news coverage?

Media coverage about ADMA stock has been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ADMA Biologics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about ADMA Biologics
.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.53%), Assenagon Asset Management S.A. (0.48%), Avantax Advisory Services Inc. (0.18%), SG Americas Securities LLC (0.14%), Leap Investments LP (0.12%) and AE Wealth Management LLC (0.12%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics
.

Which institutional investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc., and SG Americas Securities LLC.
View insider buying and selling activity for ADMA Biologics
.

Which institutional investors are buying ADMA Biologics stock?

ADMA stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Assenagon Asset Management S.A., Leap Investments LP, AE Wealth Management LLC, Principal Financial Group Inc., Raymond James Financial Services Advisors Inc., Aigen Investment Management LP, and Exane Derivatives. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics
.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.87.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $247.81 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.